Missouri Roundup Cancer Lawsuit: The $7.25 Billion Settlement, the Supreme Court, and What Your Rights Look Like Right Now
If you used Roundup and later heard the words non-Hodgkin lymphoma from a doctor, you are reading this at a moment unlike any other in the history of this litigation. Three things have converged at once, and each one could change what your claim is worth — or whether you still have one at all. A federal judge just sent the $7.25 billion class action settlement back to a St. Louis courtroom. A deadline you may never have heard of — June 4, 2026 — has already passed, and if you did not opt out by that date, you may be bound by settlement terms that stretch into the 2040s. And the United States Supreme Court is preparing a ruling that could, depending on how it comes down, eliminate the right of people in your situation to sue Bayer in state court at all. We are Attorney911 — The Manginello Law Firm, PLLC, and this page is for one person: someone in Missouri who used a glyphosate herbicide, developed cancer, and needs to understand — right now, today — where they stand and what options remain.
We handle toxic tort and product liability cases for people whose lives were changed by products they were told were safe. We are writing to you as the senior trial team that takes these cases — not as commentators on a news story, and not as the attorneys who structured this settlement or the attorneys objecting to it. We have no part in the $7.25 billion deal. What we have is the knowledge to help you figure out whether you are inside it, outside it, or trapped by it — and what to do about it. The call is free. The consultation is free. And we do not get paid unless we win your case.
The $7.25 Billion Settlement Explained: Who Gets Paid, How Much, and the $675 Million Fee Controversy
Bayer announced the class action settlement in February 2026 in coordination with a group of supporting plaintiffs’ attorneys. The St. Louis judge granted preliminary approval quickly. The structure is this: a $7.25 billion fund that would resolve tens of thousands of claims by people who attribute their non-Hodgkin lymphoma to glyphosate exposure, plus a “futures class” of individuals who do not currently have cancer but may develop it in the years ahead.
The objecting attorneys — who represent their own Roundup clients and who fought to slow or kill the deal — argue the structure is fundamentally unfair. Their central objection is a number that tells its own story: $675 million in attorney fees would go to the lawyers who put the deal together with Bayer and are helping promote it, while the cancer patients who make up the class would receive payments that, when divided across tens of thousands of claimants, amount to a fraction of what individual litigation has produced.
Bayer has stated publicly that the settlement “is fair to all parties and the objections have no merit.” The objecting attorneys see it differently. They argue the deal would, in their words, “free one of the Nation’s most notorious, long-term polluters from jury trials and real liability for their misdeeds” — because under the settlement, Bayer could continue selling Roundup without cancer warnings, and the class members would give up their right to have a jury hear their individual story.
“the class settlement, which is supported by plaintiffs’ counsel representing tens of thousands of potential class members, is fair to all parties and the objections have no merit” — Bayer’s public statement on the settlement
That last point — the continued sale without warnings — is one of the most contested features of the deal. The objecting attorneys argue that a settlement that allows Bayer to keep selling the product without a cancer warning label is a settlement that prioritizes the company’s commercial interests over the safety of future users. The deal-making attorneys counter that without the settlement, plaintiffs could be caught indefinitely in a backlog of thousands of cases and may never receive any compensation — and they point to the threat of a company bankruptcy as a real possibility that the settlement avoids.
Both sides have a point. That is what makes this moment so difficult for the individual cancer patient trying to figure out what to do.
The Supreme Court FIFRA Case: Why a Ruling “Any Day” Could Eliminate Your Right to Sue
While the settlement battle plays out in St. Louis, a separate and potentially more consequential fight is unfolding in Washington. Bayer has asked the United States Supreme Court to rule that the company is protected from state-court lawsuits alleging it failed to warn Roundup users of a cancer risk.
The legal argument runs through the Federal Insecticide, Fungicide, and Rodenticide Act — FIFRA — the federal law under which the Environmental Protection Agency registers pesticide products and approves their labeling. Bayer’s position is this: under FIFRA, if the EPA has reviewed a pesticide product and has not found a cancer risk that would require a warning, then juries in state courts cannot hold the company liable for failing to warn of a cancer risk that the federal regulator did not require.
The EPA’s current position is that glyphosate is “unlikely” to be carcinogenic to humans. Bayer argues that this federal regulatory determination should shield it from state tort law claims demanding a warning the EPA did not require.
The Supreme Court heard oral arguments in the case in April 2026. A ruling is expected at any time.
Here is why this is the single most consequential legal event in the Roundup litigation, and why it matters to you personally:
If the Supreme Court agrees with Bayer, the practical effect could be the elimination of state-court failure-to-warn claims against Bayer nationwide. The core theory of Roundup liability — that Monsanto knew or should have known about a cancer risk and failed to warn consumers — would be preempted by federal law in states where the EPA has not required a cancer warning. Individual lawsuits would lose their primary legal foundation. The class settlement, with its tier-based payment structure, could become the only path to any recovery for many claimants.
If the Supreme Court rules against Bayer, or rules narrowly, state-court failure-to-warn claims would survive. Individual litigation would retain its full value. And the class settlement — which many objectors argue undervalues claims precisely because it was structured under the threat of preemption — would look very different in a landscape where the right to a jury trial remains intact.
The uncertainty of this ruling is exactly why anyone with a Roundup cancer claim needs to be talking to a lawyer right now, not after the ruling comes down. The strategic landscape shifts entirely depending on what the Supreme Court says. Some options that exist today may not exist next month. Some options that seem closed today may open wide. You need a plan for both outcomes.
Bayer and Monsanto: The Corporate Defendant Behind the Deal
The company at the center of this litigation is Bayer AG, the German pharmaceutical and life-s sciences conglomerate that acquired Monsanto Company in 2018. When Bayer bought Monsanto, it assumed all tort liability for Roundup-related claims — and it inherited a litigation landscape that has cost the company billions of dollars in settlements and jury awards.
Monsanto Company is the original manufacturer, marketer, and distributor of Roundup and other glyphosate-based herbicides. The product has been on the market since the 1970s and became one of the most widely used herbicides in the world, particularly after the introduction of glyphosate-resistant “Roundup Ready” crops. The active ingredient — glyphosate — is what plaintiffs allege causes non-Hodgkin lymphoma, and it is what the International Agency for Research on Cancer classified in 2015 as “probably carcinogenic to humans” — a classification that Monsanto and now Bayer have contested vigorously.
Bayer is a deep-pocket defendant with global revenue sufficient to fund a multi-billion-dollar settlement and individual verdicts. The company is not going to disappear. But it is also a defendant that has used every available legal, regulatory, and procedural tool to manage its liability — from the class settlement structure to the Supreme Court preemption argument to the suggestion that a company bankruptcy is a possibility if the litigation does not resolve.
Understanding Bayer as a defendant means understanding that the company is running a multi-front strategy. The settlement is one front. The Supreme Court case is another. The continued sale of Roundup without a cancer warning is another. Each front is designed to limit the company’s exposure while preserving its commercial interests. The question for any individual claimant is whether your interests align with the company’s strategy — which is what the class settlement assumes — or whether your individual case deserves its own fight.
Missouri Product Liability Law: Your State’s Advantage
Missouri product liability law provides a framework that is, in several critical respects, favorable to plaintiffs in Roundup-type cases. Understanding these advantages is essential to evaluating whether your individual case is worth more than what the class settlement offers.
First, Missouri does not impose non-economic damage caps in product liability cases. Unlike medical malpractice actions — where Missouri caps non-economic damages — product liability claims are not subject to those caps. This means that in an individual Roundup case filed in Missouri, a jury can award the full measure of pain and suffering, emotional distress, loss of quality of life, and fear of recurrence without a statutory ceiling cutting the number down. This is a significant advantage over states that cap non-economic damages in product cases.
Second, Missouri permits punitive damages upon a showing by clear and convincing evidence that the defendant acted with outrageous conduct or a conscious disregard for the safety of others. The Monsanto Papers evidence — internal documents allegedly demonstrating a deliberate corporate strategy to manipulate scientific literature and influence regulatory findings — is designed to meet exactly this standard. In an individual case where the corporate misconduct evidence is presented to a jury, the punitive damages potential is real and substantial.
Third, Missouri’s personal injury statute of limitations generally provides five years to file a claim from the date the cause of action accrues. For toxic tort cancer claims, the discovery rule is critical: the clock often does not start running on the date of exposure — which may have been years or decades ago — but rather when the plaintiff discovered, or by reasonable diligence should have discovered, the injury and its connection to the exposure. For many Roundup plaintiffs, that accrual date is the date of the NHL diagnosis, or the date they learned that Roundup exposure may have caused their cancer. This means that even if your exposure was years ago, your claim may still be within the limitations period. However, every state’s discovery rule has its own contours, and some states impose an outer deadline — a statute of repose — that can cut off a claim even before discovery. Missouri’s specific discovery-rule formulation should be confirmed for your individual facts.
Fourth, Missouri applies a comparative fault framework to product liability actions. The durable principle is this: your own share of fault, if any, reduces your recovery by your percentage — but it may not automatically erase it. The specific threshold at which fault bars recovery has been the subject of legislative attention in Missouri, and the current rule should be confirmed for your case. What matters for most Roundup plaintiffs is that comparative fault is rarely a major factor — the typical claimant used a consumer product as directed, and the defense’s ability to assign meaningful fault to the plaintiff is limited.
Fifth, the venue matters. The Circuit Court for the City of St. Louis — where the class settlement is proceeding — is a court with extensive experience in mass tort litigation and a jury pool that has historically been receptive to corporate accountability arguments. For an individual case, the venue question is more nuanced: Missouri has specific rules about where a plaintiff can file, and the best venue for your individual case depends on where you live, where the exposure occurred, and where Bayer/Monsanto does business in the state.
Class Settlement vs. Individual Lawsuit: Which Path Is Right for You
The central decision for any Roundup-exposed NHL patient is whether the class settlement serves their interests or whether an individual case would produce a better outcome. This is not a one-size-fits-all answer. It depends on facts that are specific to you.
The class settlement offers certainty. If you are a current NHL claimant in the class, you would receive a payment from the settlement fund based on a tier structure that accounts for the severity of your disease, your treatment history, and your exposure documentation. The objecting attorneys argue that these tier payments are modest — potentially in the range of $50,000 to $150,000 for a claimant with a moderate treatment history, after the $675 million in attorney fees is taken from the fund. That range is a fraction of what individual litigation has produced in cases where the evidence was strong.
The class settlement also offers speed. The deal-making attorneys argue that without the settlement, plaintiffs could be stuck in a backlog of thousands of cases for years, with no guarantee of any recovery. They point to the risk of a Bayer bankruptcy as a reason to accept a guaranteed payment now rather than risk getting nothing later.
An individual lawsuit offers the potential for a much larger recovery — potentially $500,000 to $10,000,000 or more, depending on the strength of your exposure documentation, the severity of your disease and treatment course, the quality of your specific causation evidence, and the impact of the Monsanto corporate-misconduct documents on a jury’s willingness to award punitive damages. Early bellwether verdicts in the Roundup MDL produced significant jury awards — though those verdicts have had mixed procedural outcomes, with some reduced on appeal and the specific amounts and their current status must be verified individually.
But an individual lawsuit also carries risks. The Supreme Court’s pending FIFRA ruling could, if decided in Bayer’s favor, eliminate the core failure-to-warn theory that underlies most individual Roundup claims. The litigation takes time — potentially years. And there is always the risk of a defense verdict, particularly if the defense succeeds in arguing that your NHL had an alternative cause.
The decision tree looks like this:
If you opted out of the class settlement by June 4, 2026: You retained your right to file an individual lawsuit. Your case value depends on your exposure documentation, your medical records, and the legal landscape after the Supreme Court rules. You need individual counsel now.
If you did not opt out and you currently have NHL: You may be a class member entitled to a tier payment from the settlement fund. The question is whether that tier payment is adequate for your specific situation, or whether there are grounds to challenge the adequacy of the class representation for someone with your particular facts.
If you did not opt out and you do not currently have NHL: You may be a futures class member, bound by the settlement terms into the 2040s. If you develop NHL in the future, your recovery may be limited to the settlement framework. Whether this can be challenged depends on due process and adequacy-of-representation arguments that are specific to your situation.
If your family member died from NHL and had Roundup exposure: Wrongful death and survival claims may have distinct opt-out and limitation considerations. The deadline that applied to the living class member may or may not bind the estate and the statutory beneficiaries. This requires urgent review by counsel who understands both mass tort class action procedure and Missouri wrongful death law.
None of these paths can be chosen without knowing which one you are on. The first step is always the status check.
The Corporate Playbook: How Bayer Manages the Litigation
In a mass tort like this, the “adjuster playbook” looks different from a car crash case. There is no friendly insurance adjuster calling to offer you a quick check. Instead, there is a multi-billion-dollar corporate strategy designed to resolve claims at the lowest possible cost while preserving the company’s commercial interests. Here are the plays we see — and the counters to each.
Play 1: The Deal Structure. A class settlement that pays $675 million in attorney fees to the lawyers who structured the deal, while providing tier-based payments to cancer patients that may be a fraction of what their individual cases are worth. The deal-making attorneys are incentivized to push the deal through because their fee depends on it. The class members are told this is the “best available” outcome.
Counter: Independent counsel evaluates your individual claim value against the class tier. If your exposure documentation is strong, your diagnosis is confirmed, your treatment course was aggressive, and the corporate misconduct evidence supports punitive damages, your individual case may be worth multiples of the class tier payment. The “best available” framing only holds if you accept the premise that the deal is the only option — and with the Supreme Court ruling pending, that premise is not yet settled.
Play 2: The Futures Class Binding. People who have not even developed cancer are being bound to settlement terms through the 2040s, many without knowing the deadline existed or understanding that it applied to them. This is the mechanism by which Bayer limits its future liability — not by warning consumers, but by pre-binding them to a compensation framework before they are even injured.
Counter: Determine your opt-out status immediately. If you did not opt out and are now bound as a futures class member, explore whether the adequacy of representation can be challenged. A futures class member who was unaware of the proceeding, who never had cancer, and who received no individualized notice may have due process arguments that the binding is unconstitutional. These arguments are untested in this specific context, and they require individualized assessment by experienced counsel.
Play 3: The FIFRA Preemption Shield. Bayer’s simultaneous strategy at the Supreme Court — arguing that federal pesticide law should shield the company from state failure-to-warn claims because the EPA did not require a cancer warning. If this succeeds, the core legal theory of individual Roundup litigation is eliminated, and the class settlement becomes the only recovery path.
Counter: Plan for both outcomes. If the Supreme Court denies preemption, individual litigation retains its full value and the class settlement looks like a deal that was struck under a false threat. If the Supreme Court grants preemption, the class settlement may indeed become the only path — which makes understanding your class status and tier eligibility critical right now. Either way, you need a strategy that adapts to the ruling, not one that bets on a single outcome.
Play 4: The Bankruptcy Threat. The suggestion that Bayer might file for bankruptcy if the settlement fails — used to pressure claimants into accepting a deal that pays them less than their individual cases are worth. The deal-making attorneys have warned that a bankruptcy is a real possibility, framing the settlement as the safe choice.
Counter: Bayer is a global corporation with substantial ongoing revenue and operations. A bankruptcy filing is a litigation tactic, not a certainty. Even if Bayer were to file, a bankruptcy would likely preserve a claims fund — as we have seen in the talc litigation, where bankruptcy trusts were established to pay claimants. Accepting a fraction of your claim’s value out of fear of a threat that may never materialize is a decision that should be made with full information, not under pressure.
Play 5: Continued Sales Without Warnings. Under the settlement, Bayer can continue selling Roundup without a cancer warning label. This means future users remain exposed to the same product that plaintiffs allege caused their cancer — and the settlement does nothing to change that.
Counter: The fact that the settlement allows continued sales without warnings is itself evidence of the deal’s inadequacy from a public safety perspective. It is also a fact that a jury in an individual case would hear — that the company settled thousands of cancer claims while simultaneously preserving its right to keep selling the product without warning future users. This is the kind of evidence that drives punitive damages.
Wrongful Death and Survival Claims: Special Considerations for Families
If you lost a family member to non-Hodgkin lymphoma and that person had a history of Roundup or glyphosate exposure, the legal landscape for your family is different from that of a living plaintiff — and the differences require urgent attention.
Wrongful death claims in Missouri are governed by Missouri’s wrongful death statutes, which define who may bring the claim (the surviving spouse, children, or parents, in a defined hierarchy), what damages are recoverable (the financial support the deceased would have provided, the services they performed, the companionship and guidance lost, funeral expenses, and in some cases the pain and suffering of the deceased before death), and the time limits for filing.
The class settlement’s opt-out deadline of June 4, 2026 may or may not bind the estate and statutory beneficiaries of a person who died before that date. The interaction between class action procedure and wrongful death law is complex — a deceased class member’s estate may have separate rights, and the adequacy of representation for the estate may be different from the adequacy of representation for living class members. If your family member died before the opt-out deadline and you did not receive individualized notice of the settlement and the deadline, there may be grounds to challenge whether the estate is bound.
If your family member died after the opt-out deadline, the question is whether their existing rights — whatever they were at the time of death — passed to the estate and beneficiaries, and whether those rights are now governed by the class settlement terms or by Missouri’s wrongful death and survival statutes.
These questions cannot be answered generically. They require a review of your family member’s exposure history, medical records, date of diagnosis, date of death, whether any claim was filed before death, whether the estate has been opened, who the statutory beneficiaries are, and what notice — if any — the family received about the class settlement and the opt-out deadline. If you are in this situation, you need to talk to a lawyer now, not after the Supreme Court rules or the settlement is approved.
Frequently Asked Questions
I used Roundup and have non-Hodgkin lymphoma, but I never heard about the June 4, 2026 opt-out deadline. Am I bound by the settlement?
You may be. The settlement was designed to include a class of current NHL claimants and a futures class of people who may develop NHL in the future. If you did not opt out by the deadline, you may be bound by the settlement terms. However, whether you received adequate notice, whether the class representation was adequate for someone in your specific situation, and whether there are grounds to challenge the binding are questions that require individualized legal assessment. If you never received notice at all, that fact itself may be legally significant. Call us to discuss your specific circumstances.
What happens if the Supreme Court rules in Bayer’s favor on the FIFRA preemption question?
If the Supreme Court holds that FIFRA preempts state-law failure-to-warn claims when the EPA has not required a cancer warning, the practical effect could be the elimination of the core legal theory that underlies most individual Roundup lawsuits. State courts would be barred from holding Bayer liable for failing to warn of a cancer risk that the federal regulator did not require. This would make the class settlement — with its tier-based payment structure — the primary or only path to recovery for many claimants. It would also dramatically change the strategic landscape for anyone with an individual case, potentially reducing the value of claims that depend on failure-to-warn theories.
What happens if the Supreme Court rules against Bayer?
If the Court rules against Bayer or rules narrowly, state-court failure-to-warn claims would survive. Individual litigation would retain its full value. The class settlement — which was structured under the threat of preemption — may look very different in a world where the right to a jury trial on the failure-to-warn theory remains intact. For claimants who opted out of the class and retained individual litigation rights, this outcome would be favorable. For claimants who are bound by the class settlement, the ruling may provide grounds to argue that the settlement undervalued their claims based on a preemption threat that did not materialize.
How much would I get from the class settlement vs. an individual lawsuit?
The class settlement tier payments for a current NHL claimant with a moderate treatment history may be in the range of $50,000 to $150,000, based on the structure of the $7.25 billion fund after $675 million in attorney fees is deducted and the fund is divided across tens of thousands of claimants. Individual lawsuit values depend on exposure documentation, medical severity, treatment costs, and the corporate misconduct evidence, and can range from $500,000 to several million dollars or more — particularly in Missouri, where non-economic damages are uncapped in product liability cases and punitive damages are available. However, individual litigation carries risks — the Supreme Court ruling, the time involved, and the possibility of a defense verdict — that the class settlement does not. The right choice depends on your specific facts.
My family member died from non-Hodgkin lymphoma after years of Roundup use. Do we still have a claim?
You may. Missouri’s wrongful death statutes allow surviving family members to bring a claim for the death of a loved one caused by another’s wrongdoing. The class settlement’s opt-out deadline may or may not bind your family member’s estate — this depends on when they died, whether they had a pending claim, whether the estate received notice, and how the class action procedures interact with Missouri’s wrongful death law. If your family member died before the opt-out deadline and you did not receive individualized notice, there may be grounds to challenge whether the estate is bound. This requires urgent review by experienced counsel.
I used Roundup but I do not have cancer. Should I be worried about the futures class?
If you used Roundup products and did not opt out of the class settlement by June 4, 2026, you may be a member of the futures class — bound by the settlement’s terms if you develop non-Hodgkin lymphoma in the future, potentially through the 2040s. The futures class is one of the most contested features of the settlement, because it binds people who have not been injured, many of whom were unaware of the proceeding. Whether this binding can be challenged on due process or adequacy-of-representation grounds is a live legal question. If you are concerned about your futures class status, you should talk to a lawyer to understand your options.
How long do I have to file a Roundup cancer lawsuit in Missouri?
Missouri’s personal injury statute of limitations generally provides five years to file a claim from the date the cause of action accrues. For toxic tort cancer claims, the discovery rule is critical — the clock often does not start running from the date of exposure, but from when you discovered or reasonably should have discovered that your cancer was connected to Roundup use. For many plaintiffs, that date is the date of their NHL diagnosis or the date they first learned of the potential connection. However, statute of limitations law is state-specific and the exact formulation should be confirmed for your individual facts. Some states also impose a statute of repose — an outer deadline that can cut off a claim regardless of discovery. Do not assume you have plenty of time. Call us to confirm the deadline that applies to your case.
What does it cost to hire Attorney911 for a Roundup case?
We work on contingency. That means you pay nothing upfront and nothing out of pocket. Our fee is 33.33% of the recovery before trial and 40% if the case goes to trial. We do not get paid unless we win your case. The consultation is free. The call is free. We serve clients in English and in Spanish — hablamos Español — and our staff is available 24 hours a day, 7 days a week. You will never get an answering service when you call us.
Why Attorney911
Ralph Manginello has spent 27-plus years in courtrooms, including federal court. He was a journalist before he was a lawyer — he knows how to find the story the documents tell, and he knows how to tell it to a jury. He is the managing partner of this firm, licensed in Texas since 1998, admitted to the U.S. District Court for the Southern District of Texas, and a member of the Texas Trial Lawyers Association, the Houston Bar Association, the Harris County Criminal Lawyers Association, the National Association of Criminal Defense Lawyers, and the Pro Bono College of the State Bar of Texas. He leads the firm’s active $10 million hazing lawsuit filed in Harris County. He does not lose cases quietly.
Lupe Peña spent years inside a national insurance-defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue people exactly like you. He sat in the meetings where claims were valued using software like Colossus, where IME doctors were selected to produce the reports the defense needed, where surveillance was ordered, where delay tactics were deployed. He now sits on your side of the table. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter. He is a third-generation Texan with family roots that run deep in the state.
Our firm has recovered more than $50 million for our clients — a figure that includes a $5 million-plus brain-injury settlement, a $3.8 million-plus amputation settlement, a $2.5 million-plus truck-crash recovery, and a $2 million-plus maritime back-injury settlement. We say these numbers not to boast but because they are what we have actually done, verified and documented. Past results depend on the facts of each case and do not guarantee future outcomes. What we guarantee is that when you call, you get a real person, 24 hours a day, who will listen to your situation and help you understand your options.
The firm is based in Houston, Texas. We take cases in Missouri, working with local counsel and pro hac vice admission where required. We do not claim a Missouri office or a Missouri bar admission — and we do not need to, because the rules of professional conduct allow experienced trial counsel from one state to represent clients in another when properly associated with local counsel. What we bring is the national mass tort experience, the insider knowledge of how claims are valued and defended, and the willingness to fight for what your case is actually worth — not what a class settlement tier says it is worth.
The call is 1-888-ATTY-911. That is 1-888-288-9911. It rings to a live person, not a machine, at any hour of any day. The consultation is free. There is no fee unless we win your case.
If you used Roundup and developed non-Hodgkin lymphoma, the decisions you make in the coming weeks — before the Supreme Court rules, before the settlement is approved, before the evidence disappears — may determine what your claim is worth for the rest of your life. Do not make those decisions alone. Call us. We will help you figure out where you stand, and we will tell you the truth about what comes next.
98% of personal injury cases settle — will yours? That is a question that depends entirely on whether the person making the decision has the information and the counsel to know when a settlement is fair and when it is not. In the Roundup litigation, the difference between a fair settlement and one that undervalues your life may be measured in the millions. Call us at 1-888-ATTY-911. We are ready.